Tisumor 12,5 Mg, 25 Mg, 37,5 Mg And 50 Mg 12,5 mg/ 25 mg/ 37,5 mg/ 50 mg Capsule
PDF Leaflet Revision Date: 26 July 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of GIST after imatinib failure and advanced/metastatic renal cell carcinoma.
Dosage (summary)
50 mg orally once daily for 4 weeks, followed by a 2-week rest.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
- Paediatric population
Pregnancy & Breastfeeding
Contraindicated in pregnancy; avoid breastfeeding.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
Contraindications
- Hypersensitivity to sunitinib or excipients
Common side effects
- Hypertension
- Fatigue
- Gastrointestinal disorders
- Skin discolouration
Counselling Points
- Monitor for hypertension
- Avoid pregnancy
- Report signs of severe skin reactions
- Regular blood tests for liver function
Serious warnings
- Severe cutaneous reactions
- Cardiovascular events
- Haemorrhagic events
- Thrombotic microangiopathy
Important Disclaimer
The Tisumor 12,5 Mg, 25 Mg, 37,5 Mg And 50 Mg 12,5 mg/ 25 mg/ 37,5 mg/ 50 mg Capsule professional information leaflet below is the property of Eurolab and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
